PMVP Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to PMV Pharmaceuticals's net margin of --. PMV Pharmaceuticals's return on equity of -- beat CEL-SCI's return on equity of --.

PMV Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 317.27%. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 1787.1%. Given that CEL-SCI has higher upside potential than PMV Pharmaceuticals, analysts believe CEL-SCI is more attractive than PMV Pharmaceuticals.

PMV Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.718%.

PMV Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PMV Pharmaceuticals pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

PMV Pharmaceuticals quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. PMV Pharmaceuticals's net income of -$19.2M is lower than CEL-SCI's net income of -$6.9M. Notably, PMV Pharmaceuticals's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to PMV Pharmaceuticals's net margin of -416.75%. PMV Pharmaceuticals's return on equity of -- beat IGC Pharma's return on equity of -137.43%.

PMV Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 317.27%. On the other hand IGC Pharma has an analysts' consensus of $3.63 which suggests that it could grow by 1026.13%. Given that IGC Pharma has higher upside potential than PMV Pharmaceuticals, analysts believe IGC Pharma is more attractive than PMV Pharmaceuticals.

PMV Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.325, suggesting its more volatile than the S&P 500 by 32.462%.

PMV Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PMV Pharmaceuticals pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

PMV Pharmaceuticals quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $412K. PMV Pharmaceuticals's net income of -$19.2M is lower than IGC Pharma's net income of -$1.7M. Notably, PMV Pharmaceuticals's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals is -- versus 19.48x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Kronos Bio has a net margin of -- compared to PMV Pharmaceuticals's net margin of -595.27%. PMV Pharmaceuticals's return on equity of -- beat Kronos Bio's return on equity of -60.36%.

PMV Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 317.27%. On the other hand Kronos Bio has an analysts' consensus of -- which suggests that it could grow by 129.59%. Given that PMV Pharmaceuticals has higher upside potential than Kronos Bio, analysts believe PMV Pharmaceuticals is more attractive than Kronos Bio.

PMV Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kronos Bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

PMV Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kronos Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PMV Pharmaceuticals pays -- of its earnings as a dividend. Kronos Bio pays out -- of its earnings as a dividend.

PMV Pharmaceuticals quarterly revenues are --, which are smaller than Kronos Bio quarterly revenues of $2.4M. PMV Pharmaceuticals's net income of -$19.2M is lower than Kronos Bio's net income of -$14.1M. Notably, PMV Pharmaceuticals's price-to-earnings ratio is -- while Kronos Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals is -- versus 5.92x for Kronos Bio. Usually stocks with elevated PS ratios are considered overvalued.

Marker Therapeutics has a net margin of -- compared to PMV Pharmaceuticals's net margin of --. PMV Pharmaceuticals's return on equity of -- beat Marker Therapeutics's return on equity of --.

PMV Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 317.27%. On the other hand Marker Therapeutics has an analysts' consensus of $19.00 which suggests that it could grow by 590.91%. Given that Marker Therapeutics has higher upside potential than PMV Pharmaceuticals, analysts believe Marker Therapeutics is more attractive than PMV Pharmaceuticals.

PMV Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Marker Therapeutics has a beta of 1.484, suggesting its more volatile than the S&P 500 by 48.378%.

PMV Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PMV Pharmaceuticals pays -- of its earnings as a dividend. Marker Therapeutics pays out -- of its earnings as a dividend.

PMV Pharmaceuticals quarterly revenues are --, which are smaller than Marker Therapeutics quarterly revenues of --. PMV Pharmaceuticals's net income of -$19.2M is lower than Marker Therapeutics's net income of -$2.3M. Notably, PMV Pharmaceuticals's price-to-earnings ratio is -- while Marker Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals is -- versus -- for Marker Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.